San Diego-primarily based Viking Therapeutics marked alone as a significant competitor in the weight loss drug market place in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection As well as in